Catalyst
Slingshot members are tracking this event:
Phase 3 LAVOLTA III Study Readout of Lebrikizumab For Severe Asthma Expected mid 2017
- Source Link:
- http://www.roche.com/irp160128-a.pdf
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 19, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT01867125
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Lebrikizumab, Severe Asthma, Phase 3 Data
